Edgar G Dorsey-Trevino1,2, Varinderpal Kaur3,4, Josep M Mercader1,3,4, Jose C Florez1,3,4, Aaron Leong1,2,3,4. 1. Department of Medicine, Harvard Medical School, Boston, MA 02115, USA. 2. Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. 3. Diabetes Unit and Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA 02114, USA. 4. Programs in Metabolism and Medical & Population Genetics, Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.
Abstract
CONTEXT: Polymorphisms in the gene encoding the glucagon-like peptide-1 receptor (GLP1R) are associated with type 2 diabetes but their effects on incretin levels remain unclear. OBJECTIVE: We evaluated the physiologic and hormonal effects of GLP1R genotypes before and after interventions that influence glucose physiology. DESIGN: Pharmacogenetic study conducted at 3 academic centers in Boston, Massachusetts. PARTICIPANTS: A total of 868 antidiabetic drug-naïve participants with type 2 diabetes or at risk for developing diabetes. INTERVENTIONS: We analyzed 5 variants within GLP1R (rs761387, rs10305423, rs10305441, rs742762, and rs10305492) and recorded biochemical data during a 5-mg glipizide challenge and a 75-g oral glucose tolerance test (OGTT) following 4 doses of metformin 500 mg over 2 days. MAIN OUTCOMES: We used an additive mixed-effects model to evaluate the association of these variants with glucose, insulin, and incretin levels over multiple timepoints during the OGTT. RESULTS: During the OGTT, the G-risk allele at rs761387 was associated with higher total GLP-1 (2.61 pmol/L; 95% CI, 1.0.72-4.50), active GLP-1 (2.61 pmol/L; 95% CI, 0.04-5.18), and a trend toward higher glucose (3.63; 95% CI, -0.16 to 7.42 mg/dL) per allele but was not associated with insulin. During the glipizide challenge, the G allele was associated with higher insulin levels per allele (2.01 IU/mL; 95% CI, 0.26-3.76). The other variants were not associated with any of the outcomes tested. CONCLUSIONS: GLP1R variation is associated with differences in GLP-1 levels following an OGTT load despite no differences in insulin levels, highlighting altered incretin signaling as a potential mechanism by which GLP1R variation affects T2D risk.
CONTEXT: Polymorphisms in the gene encoding the glucagon-like peptide-1 receptor (GLP1R) are associated with type 2 diabetes but their effects on incretin levels remain unclear. OBJECTIVE: We evaluated the physiologic and hormonal effects of GLP1R genotypes before and after interventions that influence glucose physiology. DESIGN: Pharmacogenetic study conducted at 3 academic centers in Boston, Massachusetts. PARTICIPANTS: A total of 868 antidiabetic drug-naïve participants with type 2 diabetes or at risk for developing diabetes. INTERVENTIONS: We analyzed 5 variants within GLP1R (rs761387, rs10305423, rs10305441, rs742762, and rs10305492) and recorded biochemical data during a 5-mg glipizide challenge and a 75-g oral glucose tolerance test (OGTT) following 4 doses of metformin 500 mg over 2 days. MAIN OUTCOMES: We used an additive mixed-effects model to evaluate the association of these variants with glucose, insulin, and incretin levels over multiple timepoints during the OGTT. RESULTS: During the OGTT, the G-risk allele at rs761387 was associated with higher total GLP-1 (2.61 pmol/L; 95% CI, 1.0.72-4.50), active GLP-1 (2.61 pmol/L; 95% CI, 0.04-5.18), and a trend toward higher glucose (3.63; 95% CI, -0.16 to 7.42 mg/dL) per allele but was not associated with insulin. During the glipizide challenge, the G allele was associated with higher insulin levels per allele (2.01 IU/mL; 95% CI, 0.26-3.76). The other variants were not associated with any of the outcomes tested. CONCLUSIONS: GLP1R variation is associated with differences in GLP-1 levels following an OGTT load despite no differences in insulin levels, highlighting altered incretin signaling as a potential mechanism by which GLP1R variation affects T2D risk.
Authors: Shaun Purcell; Benjamin Neale; Kathe Todd-Brown; Lori Thomas; Manuel A R Ferreira; David Bender; Julian Maller; Pamela Sklar; Paul I W de Bakker; Mark J Daly; Pak C Sham Journal: Am J Hum Genet Date: 2007-07-25 Impact factor: 11.025
Authors: Andrew J Mulherin; Amy H Oh; Helena Kim; Anthony Grieco; Lina M Lauffer; Patricia L Brubaker Journal: Endocrinology Date: 2011-10-04 Impact factor: 4.736
Authors: Airani Sathananthan; Chiara Dalla Man; Francesco Micheletto; Alan R Zinsmeister; Michael Camilleri; Paula D Giesler; Jeanette M Laugen; Gianna Toffolo; Robert A Rizza; Claudio Cobelli; Adrian Vella Journal: Diabetes Care Date: 2010-09 Impact factor: 19.112
Authors: Jean-Philippe Fortin; Jonathan C Schroeder; Yuantee Zhu; Martin Beinborn; Alan S Kopin Journal: J Pharmacol Exp Ther Date: 2009-10-19 Impact factor: 4.030
Authors: Sara L Pulit; Charli Stoneman; Andrew P Morris; Andrew R Wood; Craig A Glastonbury; Jessica Tyrrell; Loïc Yengo; Teresa Ferreira; Eirini Marouli; Yingjie Ji; Jian Yang; Samuel Jones; Robin Beaumont; Damien C Croteau-Chonka; Thomas W Winkler; Andrew T Hattersley; Ruth J F Loos; Joel N Hirschhorn; Peter M Visscher; Timothy M Frayling; Hanieh Yaghootkar; Cecilia M Lindgren Journal: Hum Mol Genet Date: 2019-01-01 Impact factor: 6.150
Authors: Christopher C Chang; Carson C Chow; Laurent Cam Tellier; Shashaank Vattikuti; Shaun M Purcell; James J Lee Journal: Gigascience Date: 2015-02-25 Impact factor: 6.524
Authors: Richa Saxena; Marie-France Hivert; Claudia Langenberg; Toshiko Tanaka; James S Pankow; Peter Vollenweider; Valeriya Lyssenko; Nabila Bouatia-Naji; Josée Dupuis; Anne U Jackson; W H Linda Kao; Man Li; Nicole L Glazer; Alisa K Manning; Jian'an Luan; Heather M Stringham; Inga Prokopenko; Toby Johnson; Niels Grarup; Trine W Boesgaard; Cécile Lecoeur; Peter Shrader; Jeffrey O'Connell; Erik Ingelsson; David J Couper; Kenneth Rice; Kijoung Song; Camilla H Andreasen; Christian Dina; Anna Köttgen; Olivier Le Bacquer; François Pattou; Jalal Taneera; Valgerdur Steinthorsdottir; Denis Rybin; Kristin Ardlie; Michael Sampson; Lu Qi; Mandy van Hoek; Michael N Weedon; Yurii S Aulchenko; Benjamin F Voight; Harald Grallert; Beverley Balkau; Richard N Bergman; Suzette J Bielinski; Amelie Bonnefond; Lori L Bonnycastle; Knut Borch-Johnsen; Yvonne Böttcher; Eric Brunner; Thomas A Buchanan; Suzannah J Bumpstead; Christine Cavalcanti-Proença; Guillaume Charpentier; Yii-Der Ida Chen; Peter S Chines; Francis S Collins; Marilyn Cornelis; Gabriel J Crawford; Jerome Delplanque; Alex Doney; Josephine M Egan; Michael R Erdos; Mathieu Firmann; Nita G Forouhi; Caroline S Fox; Mark O Goodarzi; Jürgen Graessler; Aroon Hingorani; Bo Isomaa; Torben Jørgensen; Mika Kivimaki; Peter Kovacs; Knut Krohn; Meena Kumari; Torsten Lauritzen; Claire Lévy-Marchal; Vladimir Mayor; Jarred B McAteer; David Meyre; Braxton D Mitchell; Karen L Mohlke; Mario A Morken; Narisu Narisu; Colin N A Palmer; Ruth Pakyz; Laura Pascoe; Felicity Payne; Daniel Pearson; Wolfgang Rathmann; Annelli Sandbaek; Avan Aihie Sayer; Laura J Scott; Stephen J Sharp; Eric Sijbrands; Andrew Singleton; David S Siscovick; Nicholas L Smith; Thomas Sparsø; Amy J Swift; Holly Syddall; Gudmar Thorleifsson; Anke Tönjes; Tiinamaija Tuomi; Jaakko Tuomilehto; Timo T Valle; Gérard Waeber; Andrew Walley; Dawn M Waterworth; Eleftheria Zeggini; Jing Hua Zhao; Thomas Illig; H Erich Wichmann; James F Wilson; Cornelia van Duijn; Frank B Hu; Andrew D Morris; Timothy M Frayling; Andrew T Hattersley; Unnur Thorsteinsdottir; Kari Stefansson; Peter Nilsson; Ann-Christine Syvänen; Alan R Shuldiner; Mark Walker; Stefan R Bornstein; Peter Schwarz; Gordon H Williams; David M Nathan; Johanna Kuusisto; Markku Laakso; Cyrus Cooper; Michael Marmot; Luigi Ferrucci; Vincent Mooser; Michael Stumvoll; Ruth J F Loos; David Altshuler; Bruce M Psaty; Jerome I Rotter; Eric Boerwinkle; Torben Hansen; Oluf Pedersen; Jose C Florez; Mark I McCarthy; Michael Boehnke; Inês Barroso; Robert Sladek; Philippe Froguel; James B Meigs; Leif Groop; Nicholas J Wareham; Richard M Watanabe Journal: Nat Genet Date: 2010-01-17 Impact factor: 38.330